Cancer patients who took drugs to cut the risk of anemia were twice as likely to develop blood clots in the lungs or legs as other patients, a decade-long study of more than 55,000 cancer patients has found.

A new study raises fresh safety concerns about widely used anemia medicines, finding that the drug Aranesp nearly doubled the risk of stroke in people with diabetes and chronic kidney problems who are not yet sick enough to need dialysis.

A large study being published in a major medical journal says certain kidney disease patients who get the drug Aranesp to treat anemia-related fatigue may be at greater risk of having a stroke.

New York Attorney General Andrew Cuomo and 14 other states are filing a lawsuit against Amgen, alleging that the biotech company was offering kickbacks to medical providers to increase the sale of its anemia drug Aranesp.

Biotechnology behemoth Amgen Inc. is being sued by 15 states alleging the company gave kickbacks to medical providers to help boost sales of the anemia drug Aranesp.

Biotechnology giant Amgen Inc and drug wholesaler AmerisourceBergen Corp were sued on Friday by 14 U.S. states and the District of Columbia over an alleged kickback scheme designed to boost sales of Amgen's popular anemia drug, Aranesp.

Shares of Cytokinetics Inc. plunged Thursday after the biotechnology company said development of a potential heart failure drug could take a year longer than previously anticipated.

Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report. Travelers and MMM led the Dow.

Stocks advanced Thursday as investors seemed to focus more on some big-name earnings beats and a rise in leading indicators instead of a disappointing jobless report.

Stocks slipped Thursday as investors weighed a disappointing jobless-claims report and some encouraging earnings reports.

Earnings continue to come in largely above expectations, but other factors are waylaying the stock market's recent advances - ranging from Walmart's price cuts to analyst Richard Bove's downgrade of Wells Fargo to rising oil prices. 

Amgen reported quarterly results that outpaced what Wall Street was expecting, and the company boosted its outlook for its full-year profit. But the company's shares declined in extended trading.

Stocks finished lower after well-known banking analyst Dick Bove downgraded his rating on Wells Fargo.

Stocks advanced Wednesday as investors were encouraged by a few earnings reports, including Morgan Stanley, Yahoo and SanDisk. The VIX, widely considered the best gauge of fear in the market, dropped to just above 20.

Stocks opened lower Wednesday as a raft of companies beating earning estimates but failed to impress investors.